Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene.

doi:10.1210/ENDO.137.12.8940410

Paper

Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene.

Published Dec 1, 1996 · Ying Zhao, V. Agarwal, C. Mendelson

Endocrinology

Q1 SJR score

465

Citations

8

Influential Citations

Full textSemantic Scholar

Abstract

In the present report, we show that prostaglandin (PG) E2 is the most potent factor which stimulates aromatase expression via cyclic AMP and promoter II. PGE2 acts via EP1 and EP2 receptor subtypes to stimulate both the PKC and PKA pathways. The combined stimulation of both of these pathways results in maximal expression of promoter II-specific CYP19 transcripts. Since PGE2 is a major secretory product both of breast tumor epithelial cells and fibroblasts, as well as of macrophages infiltrating the tumor site, then this could be the mechanism whereby estrogen biosynthesis is stimulated in breast sites adjacent to a tumor, leading in turn to increased growth and development of the tumor itself.

Highly Cited

Study Snapshot

PGE2 stimulates estrogen biosynthesis in breast tumors, potentially leading to increased tumor growth and development.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene.

References

Citations

Canine Mammary Cancer: State of the Art and Future Perspectives

Canine mammary cancer shares many characteristics with human breast cancer, and establishing molecular classification and targeted therapies could improve survival and reduce adverse effects.

Subchronic effect of different doses ofDiclofenac Sodium on female reproductive system in rats.

High doses of diclofenac sodium alone or combined with mefenamic acid significantly impact the female reproductive system, oxidative stress, and hematological parameters in rats.

WNT3a Signaling Inhibits Aromatase Expression in Breast Adipose Fibroblasts—A Possible Mechanism Supporting the Loss of Estrogen Responsiveness of Triple-Negative Breast Cancers

WNT3a signaling in breast tissue may contribute to the loss of estrogen responsiveness in triple-negative breast cancers by suppressing aromatase expression in breast adipose fibroblasts.

Sub-chronic effects of mefenamic acid alone or in combination with diclofenac on the female reproductive system in albino rats

Sub-chronic administration of low or high mefenamic acid dosages in rats leads to hormonal, biochemical, and histological alterations, as well as significant hematological changes.

Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer

Oestrogen deprivation in breast cancer cells increases chemokine production and immune cell recruitment, potentially impacting the combination and timing of anti-oestrogen therapies with other therapies.

Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives

Obesity is linked to reduced efficacy of conventional endocrine therapies in breast cancer patients, highlighting the need for new precision medicine-based treatments and dosing schedules.

Regulation of Estradiol Synthesis by Aromatase Interacting Partner in Breast (AIPB)

AIPB protein is a key regulator of estradiol synthesis and may predict an increased risk of developing breast cancer.

Blood Biomarkers Reflect the Effects of Obesity and Inflammation on the Human Breast Transcriptome.

Obesity and white adipose tissue inflammation in the breast lead to molecular changes linked to breast cancer development and progression, and blood biomarkers can help determine risk and prognosis.

A New Paradigm in the Relationship between Melatonin and Breast Cancer: Gut Microbiota Identified as a Potential Regulatory Agent

Gut microbiota imbalances may increase the risk of breast cancer by altering estrogen levels and reducing melatonin production, potentially affecting chemotherapy and radiotherapy side effects.